Mapua Health
Intravenous Vitamin C Therapy (IVC)High dose Vitamin C is given intravenously to treat and / or ameliorate the symptoms of a number of medical conditions.Conditions for which IVC may be useful:CancerVitamin C has quite a long history of use in treating cancer, stretching back to the 1970s ADDIN EN.CITE <EndNote><Cite><Author>Cameron</Author><Year>1973</Year><RecNum>4233</RecNum><DisplayText><style face="superscript">1</style></DisplayText><record><rec-number>4233</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4233</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Cameron, E.</author><author>Pauling, L.</author></authors></contributors><titles><title>Ascorbic acid and the glycosaminoglycans. An orthomolecular approach to cancer and other diseases</title><secondary-title>Oncology</secondary-title><alt-title>Oncology</alt-title></titles><periodical><full-title>Oncology</full-title><abbr-1>Oncology</abbr-1></periodical><alt-periodical><full-title>Oncology</full-title><abbr-1>Oncology</abbr-1></alt-periodical><pages>181-92</pages><volume>27</volume><number>2</number><edition>1973/01/01</edition><keywords><keyword>Animals</keyword><keyword>Ascorbic Acid/ metabolism/therapeutic use</keyword><keyword>Cell Division</keyword><keyword>Glycosaminoglycans/ metabolism</keyword><keyword>Hormones/therapeutic use</keyword><keyword>Humans</keyword><keyword>Hyaluronoglucosaminidase/antagonists & inhibitors/physiology</keyword><keyword>Neoplasms/ metabolism/radiotherapy</keyword><keyword>Neoplasms, Experimental/drug therapy</keyword><keyword>Scurvy/drug therapy/metabolism</keyword></keywords><dates><year>1973</year></dates><isbn>0030-2414 (Print)
0030-2414 (Linking)</isbn><accession-num>4267127</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>1 and has been used extensively since then ADDIN EN.CITE <EndNote><Cite><Author>Mikirova</Author><Year>2013</Year><RecNum>4261</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>4261</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mikirova, N.A.; Casciari, J.J.; Hunninghake, R.E.; Riordan, N.H</author></authors></contributors><titles><title>Intravenous ascorbic acid protocol for cancer patients: scientifice rationale, pharmacology, and clinical experience</title><secondary-title>Functional Foods in Health and Disease</secondary-title></titles><periodical><full-title>Functional Foods in Health and Disease</full-title></periodical><pages>344-366</pages><volume>3</volume><number>8</number><dates><year>2013</year></dates><urls></urls></record></Cite></EndNote>2, although it remains controversial within the medical community. Much of the more recent research has been done in the laboratory, in animals and in people with advanced cancer.Vitamin C, in very high doses can be used in cancer:as an adjunct to chemotherapy, enhancing the effect of the chemotherapy drug to kill the cancer cellsPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BYmRlbC1MYXRpZjwvQXV0aG9yPjxZZWFyPjIwMDU8L1ll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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BYmRlbC1MYXRpZjwvQXV0aG9yPjxZZWFyPjIwMDU8L1ll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ADDIN EN.CITE.DATA 3with chemotherapy to help to reduce the side-effects ADDIN EN.CITE <EndNote><Cite><Author>Drisko</Author><Year>2003</Year><RecNum>4256</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>4256</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Drisko, J. A.</author><author>Chapman, J.</author><author>Hunter, V. J.</author></authors></contributors><auth-address>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Kansas Medical Center, 39012 Rainbow Boulevard, Kansas City, KS 66160, USA. jdrisko@kumc.edu</auth-address><titles><title>The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer</title><secondary-title>J Am Coll Nutr</secondary-title><alt-title>Journal of the American College of Nutrition</alt-title></titles><periodical><full-title>J Am Coll Nutr</full-title></periodical><pages>118-23</pages><volume>22</volume><number>2</number><edition>2003/04/04</edition><keywords><keyword>Adenocarcinoma, Papillary/ drug therapy</keyword><keyword>Antineoplastic Agents/ therapeutic use</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols/ therapeutic use</keyword><keyword>Antioxidants/ therapeutic use</keyword><keyword>Carboplatin/therapeutic use</keyword><keyword>Complementary Therapies</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Middle Aged</keyword><keyword>Neoplasm Recurrence, Local</keyword><keyword>Ovarian Neoplasms/ drug therapy</keyword><keyword>Paclitaxel/therapeutic use</keyword><keyword>Treatment Outcome</keyword><keyword>Vitamins/therapeutic use</keyword></keywords><dates><year>2003</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>0731-5724 (Print)
0731-5724 (Linking)</isbn><accession-num>12672707</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>4as a chemotherapeutic (cancer killing) agent in itselfPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Hb256YWxlejwvQXV0aG9yPjxZZWFyPjIwMDU8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Hb256YWxlejwvQXV0aG9yPjxZZWFyPjIwMDU8L1llYXI+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ADDIN EN.CITE.DATA 5improve quality of life ADDIN EN.CITE <EndNote><Cite><Author>Yeom</Author><Year>2007</Year><RecNum>4263</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>4263</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4263</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Yeom, C. H.</author><author>Jung, G. C.</author><author>Song, K. J.</author></authors></contributors><auth-address>Department of Family Medicine, Myongji Hospital, Kwandong University College of Medicine, Goyang, Korea.</auth-address><titles><title>Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration</title><secondary-title>J Korean Med Sci</secondary-title><alt-title>Journal of Korean medical science</alt-title></titles><periodical><full-title>J Korean Med Sci</full-title><abbr-1>Journal of Korean medical science</abbr-1></periodical><alt-periodical><full-title>J Korean Med Sci</full-title><abbr-1>Journal of Korean medical science</abbr-1></alt-periodical><pages>7-11</pages><volume>22</volume><number>1</number><edition>2007/02/14</edition><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Ascorbic Acid/ administration & dosage</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Neoplasms/psychology</keyword><keyword>Quality of Life</keyword><keyword>Terminal Care</keyword></keywords><dates><year>2007</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1011-8934 (Print)
1011-8934 (Linking)</isbn><accession-num>17297243</accession-num><urls></urls><custom2>PMC2693571</custom2><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>6Vitamin C taken by mouth (even in the same doses as are given intravenously) does not result in high enough levels of Vitamin C in the blood to fight cancer cells. ADDIN EN.CITE <EndNote><Cite><Author>Padayatty</Author><Year>2004</Year><RecNum>4235</RecNum><DisplayText><style face="superscript">7</style></DisplayText><record><rec-number>4235</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4235</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Padayatty, S. J.</author><author>Sun, H.</author><author>Wang, Y.</author><author>Riordan, H. D.</author><author>Hewitt, S. M.</author><author>Katz, A.</author><author>Wesley, R. A.</author><author>Levine, M.</author></authors></contributors><auth-address>National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institut, and the Clinical Center, National Institutes of Health, Bethesda, Maryland 20892-1372, USA.</auth-address><titles><title>Vitamin C pharmacokinetics: implications for oral and intravenous use</title><secondary-title>Ann Intern Med</secondary-title><alt-title>Annals of internal medicine</alt-title></titles><periodical><full-title>Ann Intern Med</full-title></periodical><alt-periodical><full-title>Annals of Internal Medicine</full-title></alt-periodical><pages>533-7</pages><volume>140</volume><number>7</number><edition>2004/04/08</edition><keywords><keyword>Administration, Oral</keyword><keyword>Adult</keyword><keyword>Antineoplastic Agents/therapeutic use</keyword><keyword>Ascorbic Acid/ administration & dosage/ pharmacokinetics/therapeutic use</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Injections, Intravenous</keyword><keyword>Male</keyword><keyword>Reference Values</keyword></keywords><dates><year>2004</year><pub-dates><date>Apr 6</date></pub-dates></dates><isbn>1539-3704 (Electronic)
0003-4819 (Linking)</isbn><accession-num>15068981</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>7 This is probably due to a number of factors including the way the body controls the uptake of Vitamin C from the bowel. ADDIN EN.CITE <EndNote><Cite><Author>Levine</Author><Year>2005</Year><RecNum>4236</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>4236</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4236</key></foreign-keys><ref-type name="Book Section">5</ref-type><contributors><authors><author>Levine, M.; Kats, A.; Padayatty, S.J.</author></authors><secondary-authors><author>Shils, M.E.</author></secondary-authors></contributors><titles><title>Vitamin C</title><secondary-title>Modern Nutrtion in Helath and Disease</secondary-title></titles><dates><year>2005</year></dates><pub-location>Balitmore</pub-location><publisher>Lippincott Williams & Wilkins</publisher><urls></urls></record></Cite></EndNote>8 This is why it is necessary to give Vitamin C intravenously. In one study patients with the highest concentration of Vitamin C in the blood were able to maintain their physical quality of life, despite suffering with advanced cancer.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib2ZmZXI8L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib2ZmZXI8L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFyPjxS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ADDIN EN.CITE.DATA 9IVC and other anti-oxidants appear to enhance the cancer-killing effects of chemotherapy and radiation, although how this works is not fully understood.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BYmRlbC1MYXRpZjwvQXV0aG9yPjxZZWFyPjIwMDU8L1ll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==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BYmRlbC1MYXRpZjwvQXV0aG9yPjxZZWFyPjIwMDU8L1ll
YXI+PFJlY051bT40MjI4PC9SZWNOdW0+PERpc3BsYXlUZXh0PjxzdHlsZSBmYWNlPSJzdXBlcnNj
cmlwdCI+Myw1LDEwLDExPC9zdHlsZT48L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+
NDIyODwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjkyZHMy
NXIycnRzZXRsZWVlZXN4emRkand4eDUyMjkyMjBzeCI+NDIyODwva2V5PjwvZm9yZWlnbi1rZXlz
PjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0
b3JzPjxhdXRob3JzPjxhdXRob3I+QWJkZWwtTGF0aWYsIE0uIE0uPC9hdXRob3I+PGF1dGhvcj5S
YW91ZiwgQS4gQS48L2F1dGhvcj48YXV0aG9yPlNhYnJhLCBLLjwvYXV0aG9yPjxhdXRob3I+S2Vs
bGVoZXIsIEQuPC9hdXRob3I+PGF1dGhvcj5SZXlub2xkcywgSi4gVi48L2F1dGhvcj48L2F1dGhv
cnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIFN1cmdlcnksIFRy
aW5pdHkgQ2VudHJlIGZvciBIZWFsdGggU2NpZW5jZXMsIFN0IEphbWVzJmFwb3M7cyBIb3NwaXRh
bCwgRHVibGluLCBJcmVsYW5kLiBhYmRlbGxtbUB0Y2QuaWU8L2F1dGgtYWRkcmVzcz48dGl0bGVz
Pjx0aXRsZT5WaXRhbWluIEMgZW5oYW5jZXMgY2hlbW9zZW5zaXRpemF0aW9uIG9mIGVzb3BoYWdl
YWwgY2FuY2VyIGNlbGxzIGluIHZpdHJvPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkogQ2hlbW90
aGVyPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5Kb3VybmFsIG9mIGNoZW1vdGhlcmFweSAo
RmxvcmVuY2UsIEl0YWx5KTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRp
dGxlPkogQ2hlbW90aGVyPC9mdWxsLXRpdGxlPjxhYmJyLTE+Sm91cm5hbCBvZiBjaGVtb3RoZXJh
cHkgKEZsb3JlbmNlLCBJdGFseSk8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2Fs
PjxmdWxsLXRpdGxlPkogQ2hlbW90aGVyPC9mdWxsLXRpdGxlPjxhYmJyLTE+Sm91cm5hbCBvZiBj
aGVtb3RoZXJhcHkgKEZsb3JlbmNlLCBJdGFseSk8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxw
YWdlcz41MzktNDk8L3BhZ2VzPjx2b2x1bWU+MTc8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48
ZWRpdGlvbj4yMDA1LzEyLzA2PC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BbnRpbWV0YWJv
bGl0ZXMsIEFudGluZW9wbGFzdGljLyBwaGFybWFjb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+QW50
aW5lb3BsYXN0aWMgQWdlbnRzLyBwaGFybWFjb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+QW50aW94
aWRhbnRzLyBwaGFybWFjb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+QXNjb3JiaWMgQWNpZC8gcGhh
cm1hY29sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkNlbGwgUHJvbGlmZXJhdGlvbjwva2V5d29yZD48
a2V5d29yZD5DaXNwbGF0aW4vIHBoYXJtYWNvbG9neTwva2V5d29yZD48a2V5d29yZD5EcnVnIElu
dGVyYWN0aW9uczwva2V5d29yZD48a2V5d29yZD5Fc29waGFnZWFsIE5lb3BsYXNtcy8gcGF0aG9s
b2d5PC9rZXl3b3JkPjxrZXl3b3JkPkZsdW9yb3VyYWNpbC8gcGhhcm1hY29sb2d5PC9rZXl3b3Jk
PjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5ORi1rYXBwYSBCL2Jpb3N5bnRoZXNp
cy9tZXRhYm9saXNtPC9rZXl3b3JkPjxrZXl3b3JkPlRyYW5zY3JpcHRpb24gRmFjdG9yIEFQLTEv
Ymlvc3ludGhlc2lzL21ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+VHVtb3IgQ2VsbHMsIEN1
bHR1cmVkPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDU8L3llYXI+PHB1Yi1k
YXRlcz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xMTIwLTAwOVgg
KFByaW50KSYjeEQ7MTEyMC0wMDlYIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4xNjMy
MzQ0NDwvYWNjZXNzaW9uLW51bT48dXJscz48L3VybHM+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRl
cj5OTE08L3JlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48
L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5TYXJuYTwvQXV0aG9yPjxZZWFyPjE5OTM8L1ll
YXI+PFJlY051bT40MjQ2PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj40MjQ2PC9yZWMtbnVt
YmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iOTJkczI1cjJydHNldGxlZWVl
c3h6ZGRqd3h4NTIyOTIyMHN4Ij40MjQ2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5h
bWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+
PGF1dGhvcj5TYXJuYSwgUy48L2F1dGhvcj48YXV0aG9yPkJob2xhLCBSLiBLLjwvYXV0aG9yPjwv
YXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgWm9vbG9n
eSwgR2F1aGF0aSBVbml2ZXJzaXR5LCBHdXdhaGF0aSwgSW5kaWEuPC9hdXRoLWFkZHJlc3M+PHRp
dGxlcz48dGl0bGU+Q2hlbW8taW1tdW5vdGhlcmFwZXV0aWNhbCBzdHVkaWVzIG9uIERhbHRvbiZh
cG9zO3MgbHltcGhvbWEgaW4gbWljZSB1c2luZyBjaXNwbGF0aW4gYW5kIGFzY29yYmljIGFjaWQ6
IHN5bmVyZ2lzdGljIGFudGl0dW1vciBlZmZlY3QgaW4gdml2byBhbmQgaW4gdml0cm88L3RpdGxl
PjxzZWNvbmRhcnktdGl0bGU+QXJjaCBJbW11bm9sIFRoZXIgRXhwIChXYXJzeik8L3NlY29uZGFy
eS10aXRsZT48YWx0LXRpdGxlPkFyY2hpdnVtIGltbXVub2xvZ2lhZSBldCB0aGVyYXBpYWUgZXhw
ZXJpbWVudGFsaXM8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5B
cmNoIEltbXVub2wgVGhlciBFeHAgKFdhcnN6KTwvZnVsbC10aXRsZT48YWJici0xPkFyY2hpdnVt
IGltbXVub2xvZ2lhZSBldCB0aGVyYXBpYWUgZXhwZXJpbWVudGFsaXM8L2FiYnItMT48L3Blcmlv
ZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkFyY2ggSW1tdW5vbCBUaGVyIEV4cCAo
V2Fyc3opPC9mdWxsLXRpdGxlPjxhYmJyLTE+QXJjaGl2dW0gaW1tdW5vbG9naWFlIGV0IHRoZXJh
cGlhZSBleHBlcmltZW50YWxpczwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjMyNy0z
MzwvcGFnZXM+PHZvbHVtZT40MTwvdm9sdW1lPjxudW1iZXI+NS02PC9udW1iZXI+PGVkaXRpb24+
MTk5My8wMS8wMTwvZWRpdGlvbj48a2V5d29yZHM+PGtleXdvcmQ+QW5pbWFsczwva2V5d29yZD48
a2V5d29yZD5BbnRpbmVvcGxhc3RpYyBDb21iaW5lZCBDaGVtb3RoZXJhcHkgUHJvdG9jb2xzLyBw
aGFybWFjb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+QXNjb3JiaWMgQWNpZC9hZG1pbmlzdHJhdGlv
biAmYW1wOyBkb3NhZ2U8L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBEaXZpc2lvbi9kcnVnIGVmZmVj
dHM8L2tleXdvcmQ+PGtleXdvcmQ+Q2lzcGxhdGluL2FkbWluaXN0cmF0aW9uICZhbXA7IGRvc2Fn
ZTwva2V5d29yZD48a2V5d29yZD5Db21iaW5lZCBNb2RhbGl0eSBUaGVyYXB5PC9rZXl3b3JkPjxr
ZXl3b3JkPkRvc2UtUmVzcG9uc2UgUmVsYXRpb25zaGlwLCBEcnVnPC9rZXl3b3JkPjxrZXl3b3Jk
PkRydWcgU3luZXJnaXNtPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29y
ZD5JbW11bm90aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPkx5bXBob21hLyBkcnVnIHRoZXJhcHkv
aW1tdW5vbG9neS8gdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3
b3JkPk1pY2U8L2tleXdvcmQ+PGtleXdvcmQ+TWljZSwgSW5icmVkIEMzSDwva2V5d29yZD48a2V5
d29yZD5OZW9wbGFzbSBUcmFuc3BsYW50YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+VHVtb3IgQ2Vs
bHMsIEN1bHR1cmVkL2RydWcgZWZmZWN0czwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVh
cj4xOTkzPC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDAwNC0wNjlYIChQcmludCkmI3hEOzAwMDQtMDY5
WCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+ODAxMDg3NDwvYWNjZXNzaW9uLW51bT48
dXJscz48L3VybHM+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3JlbW90ZS1kYXRhYmFz
ZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+
PEF1dGhvcj5OYWd5PC9BdXRob3I+PFllYXI+MjAwMzwvWWVhcj48UmVjTnVtPjQyNTQ8L1JlY051
bT48cmVjb3JkPjxyZWMtbnVtYmVyPjQyNTQ8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5
IGFwcD0iRU4iIGRiLWlkPSI5MmRzMjVyMnJ0c2V0bGVlZWVzeHpkZGp3eHg1MjI5MjIwc3giPjQy
NTQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4x
NzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk5hZ3ksIEIuPC9hdXRo
b3I+PGF1dGhvcj5NdWNzaSwgSS48L2F1dGhvcj48YXV0aG9yPk1vbG5hciwgSi48L2F1dGhvcj48
YXV0aG9yPlZhcmdhLCBBLjwvYXV0aG9yPjxhdXRob3I+VGh1cnpvLCBMLjwvYXV0aG9yPjwvYXV0
aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgT25jb3RoZXJh
cHksIFVuaXZlcnNpdHkgb2YgU3plZ2VkLCBLb3JhbnlpIEZhc29yIDEyLCBILTY3MjAgU3plZ2Vk
LCBIdW5nYXJ5LiBuYmVhdHJpeEBmcmVlbWFpbC5odTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRp
dGxlPkNoZW1vc2Vuc2l0aXppbmcgZWZmZWN0IG9mIHZpdGFtaW4gQyBpbiBjb21iaW5hdGlvbiB3
aXRoIDUtZmx1b3JvdXJhY2lsIGluIHZpdHJvPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkluIFZp
dm88L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkluIHZpdm8gKEF0aGVucywgR3JlZWNlKTwv
YWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkluIFZpdm88L2Z1bGwt
dGl0bGU+PGFiYnItMT5JbiB2aXZvIChBdGhlbnMsIEdyZWVjZSk8L2FiYnItMT48L3BlcmlvZGlj
YWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkluIFZpdm88L2Z1bGwtdGl0bGU+PGFiYnIt
MT5JbiB2aXZvIChBdGhlbnMsIEdyZWVjZSk8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdl
cz4yODktOTI8L3BhZ2VzPjx2b2x1bWU+MTc8L3ZvbHVtZT48bnVtYmVyPjM8L251bWJlcj48ZWRp
dGlvbj4yMDAzLzA4LzIyPC9lZGl0aW9uPjxrZXl3b3Jkcz48a2V5d29yZD5BbmltYWxzPC9rZXl3
b3JkPjxrZXl3b3JkPkFzY29yYmljIEFjaWQvIHBoYXJtYWNvbG9neTwva2V5d29yZD48a2V5d29y
ZD5DZWxsIERpdmlzaW9uLyBkcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBMaW5l
LCBUdW1vcjwva2V5d29yZD48a2V5d29yZD5DZWxsIFN1cnZpdmFsLyBkcnVnIGVmZmVjdHM8L2tl
eXdvcmQ+PGtleXdvcmQ+RHJ1ZyBSZXNpc3RhbmNlLCBNdWx0aXBsZS9kcnVnIGVmZmVjdHM8L2tl
eXdvcmQ+PGtleXdvcmQ+RHJ1ZyBTeW5lcmdpc208L2tleXdvcmQ+PGtleXdvcmQ+Rmx1b3JvdXJh
Y2lsL3BoYXJtYWNvbG9neTwva2V5d29yZD48a2V5d29yZD5MZXVrZW1pYSBMNTE3OC8gcGF0aG9s
b2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1pY2U8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHll
YXI+MjAwMzwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1heS1KdW48L2RhdGU+PC9wdWItZGF0ZXM+
PC9kYXRlcz48aXNibj4wMjU4LTg1MVggKFByaW50KSYjeEQ7MDI1OC04NTFYIChMaW5raW5nKTwv
aXNibj48YWNjZXNzaW9uLW51bT4xMjkyOTU4MjwvYWNjZXNzaW9uLW51bT48dXJscz48L3VybHM+
PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3JlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj48
bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5Hb256
YWxlejwvQXV0aG9yPjxZZWFyPjIwMDU8L1llYXI+PFJlY051bT40MjQ5PC9SZWNOdW0+PHJlY29y
ZD48cmVjLW51bWJlcj40MjQ5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO
IiBkYi1pZD0iOTJkczI1cjJydHNldGxlZWVlc3h6ZGRqd3h4NTIyOTIyMHN4Ij40MjQ5PC9rZXk+
PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10
eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5Hb256YWxleiwgTS4gSi48L2F1dGhv
cj48YXV0aG9yPk1pcmFuZGEtTWFzc2FyaSwgSi4gUi48L2F1dGhvcj48YXV0aG9yPk1vcmEsIEUu
IE0uPC9hdXRob3I+PGF1dGhvcj5HdXptYW4sIEEuPC9hdXRob3I+PGF1dGhvcj5SaW9yZGFuLCBO
LiBILjwvYXV0aG9yPjxhdXRob3I+UmlvcmRhbiwgSC4gRC48L2F1dGhvcj48YXV0aG9yPkNhc2Np
YXJpLCBKLiBKLjwvYXV0aG9yPjxhdXRob3I+SmFja3NvbiwgSi4gQS48L2F1dGhvcj48YXV0aG9y
PlJvbWFuLUZyYW5jbywgQS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgt
YWRkcmVzcz5Vbml2ZXJzaXR5IG9mIFB1ZXJ0byBSaWNvLCBNZWRpY2FsIFNjaWVuY2VzIENhbXB1
cywgR3JhZHVhdGUgU2Nob29sIG9mIFB1YmxpYyBIZWFsdGgsIERlcGFydG1lbnQgSHVtYW4gRGV2
ZWxvcG1lbnQsIE51dHJpdGlvbiBQcm9ncmFtLCBQTyBCb3ggMzY1MDY3LCBTYW4gSnVhbiwgUFIu
IG1nb256YWxlekByY20udXByLmVkdTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPk9ydGhv
bW9sZWN1bGFyIG9uY29sb2d5IHJldmlldzogYXNjb3JiaWMgYWNpZCBhbmQgY2FuY2VyIDI1IHll
YXJzIGxhdGVyPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkludGVnciBDYW5jZXIgVGhlcjwvc2Vj
b25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+SW50ZWdyYXRpdmUgY2FuY2VyIHRoZXJhcGllczwvYWx0
LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkludGVnciBDYW5jZXIgVGhl
cjwvZnVsbC10aXRsZT48YWJici0xPkludGVncmF0aXZlIGNhbmNlciB0aGVyYXBpZXM8L2FiYnIt
MT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkludGVnciBDYW5jZXIg
VGhlcjwvZnVsbC10aXRsZT48YWJici0xPkludGVncmF0aXZlIGNhbmNlciB0aGVyYXBpZXM8L2Fi
YnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zMi00NDwvcGFnZXM+PHZvbHVtZT40PC92b2x1
bWU+PG51bWJlcj4xPC9udW1iZXI+PGVkaXRpb24+MjAwNS8wMi8wODwvZWRpdGlvbj48a2V5d29y
ZHM+PGtleXdvcmQ+QW50aW94aWRhbnRzLyBwaGFybWFjb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+
QXNjb3JiaWMgQWNpZC9hZG1pbmlzdHJhdGlvbiAmYW1wOyBkb3NhZ2UvIHBoYXJtYWNvbG9neS8g
dGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkNsaW5pY2FsIFRyaWFscyBhcyBUb3Bp
Yzwva2V5d29yZD48a2V5d29yZD5Db21iaW5lZCBNb2RhbGl0eSBUaGVyYXB5PC9rZXl3b3JkPjxr
ZXl3b3JkPkRvc2UtUmVzcG9uc2UgUmVsYXRpb25zaGlwLCBEcnVnPC9rZXl3b3JkPjxrZXl3b3Jk
PkRydWcgUmVzaXN0YW5jZSwgTmVvcGxhc208L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3
b3JkPjxrZXl3b3JkPkluZnVzaW9ucywgSW50cmF2ZW5vdXM8L2tleXdvcmQ+PGtleXdvcmQ+TmVv
cGxhc21zLyBkcnVnIHRoZXJhcHkvIHByZXZlbnRpb24gJmFtcDsgY29udHJvbDwva2V5d29yZD48
a2V5d29yZD5QYWluL2RydWcgdGhlcmFweS9ldGlvbG9neTwva2V5d29yZD48a2V5d29yZD5QYWxs
aWF0aXZlIENhcmU8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwNTwveWVhcj48
cHViLWRhdGVzPjxkYXRlPk1hcjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE1MzQt
NzM1NCAoUHJpbnQpJiN4RDsxNTM0LTczNTQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVt
PjE1Njk1NDc2PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJj
ZS1udW0+MTAuMTE3Ny8xNTM0NzM1NDA0MjczODYxPC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48
cmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPk5MTTwvcmVtb3RlLWRhdGFiYXNlLXByb3ZpZGVyPjxs
YW5ndWFnZT5lbmc8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==
ADDIN EN.CITE.DATA 3,5,10,11 Also, IVC and other anti-oxidants may decrease the side-effects of chemotherapy and radiotherapy. ADDIN EN.CITE <EndNote><Cite><Author>Lamson</Author><Year>2000</Year><RecNum>4257</RecNum><DisplayText><style face="superscript">12</style></DisplayText><record><rec-number>4257</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4257</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Lamson, D. W.</author><author>Brignall, M. S.</author></authors></contributors><auth-address>Tahoma Clinic - Kent, WA, USA.</auth-address><titles><title>Antioxidants and cancer therapy II: quick reference guide</title><secondary-title>Altern Med Rev</secondary-title><alt-title>Alternative medicine review : a journal of clinical therapeutic</alt-title></titles><periodical><full-title>Altern Med Rev</full-title></periodical><pages>152-63</pages><volume>5</volume><number>2</number><edition>2000/04/18</edition><keywords><keyword>Antineoplastic Agents/therapeutic use</keyword><keyword>Antioxidants/ therapeutic use</keyword><keyword>Combined Modality Therapy</keyword><keyword>Humans</keyword><keyword>Neoplasms/ drug therapy/radiotherapy</keyword></keywords><dates><year>2000</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>1089-5159 (Print)
1089-5159 (Linking)</isbn><accession-num>10767670</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>12 Patients who have received IVC and other nutrients, as well as chemotherapy appear to improve more than expected. ADDIN EN.CITE <EndNote><Cite><Author>Drisko</Author><Year>2003</Year><RecNum>4256</RecNum><DisplayText><style face="superscript">4</style></DisplayText><record><rec-number>4256</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4256</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Drisko, J. A.</author><author>Chapman, J.</author><author>Hunter, V. J.</author></authors></contributors><auth-address>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Kansas Medical Center, 39012 Rainbow Boulevard, Kansas City, KS 66160, USA. jdrisko@kumc.edu</auth-address><titles><title>The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer</title><secondary-title>J Am Coll Nutr</secondary-title><alt-title>Journal of the American College of Nutrition</alt-title></titles><periodical><full-title>J Am Coll Nutr</full-title></periodical><pages>118-23</pages><volume>22</volume><number>2</number><edition>2003/04/04</edition><keywords><keyword>Adenocarcinoma, Papillary/ drug therapy</keyword><keyword>Antineoplastic Agents/ therapeutic use</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols/ therapeutic use</keyword><keyword>Antioxidants/ therapeutic use</keyword><keyword>Carboplatin/therapeutic use</keyword><keyword>Complementary Therapies</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Middle Aged</keyword><keyword>Neoplasm Recurrence, Local</keyword><keyword>Ovarian Neoplasms/ drug therapy</keyword><keyword>Paclitaxel/therapeutic use</keyword><keyword>Treatment Outcome</keyword><keyword>Vitamins/therapeutic use</keyword></keywords><dates><year>2003</year><pub-dates><date>Apr</date></pub-dates></dates><isbn>0731-5724 (Print)
0731-5724 (Linking)</isbn><accession-num>12672707</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>4 Vitamin C has not been studied in all the different types of cancer, but the general trend across the board in people with cancer is positive.While there have been reports of prolonged survival using IVC ADDIN EN.CITE <EndNote><Cite><Author>Cameron</Author><Year>1978</Year><RecNum>4237</RecNum><DisplayText><style face="superscript">13</style></DisplayText><record><rec-number>4237</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4237</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Cameron, E.</author><author>Pauling, L.</author></authors></contributors><titles><title>Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer</title><secondary-title>Proc Natl Acad Sci U S A</secondary-title><alt-title>Proceedings of the National Academy of Sciences of the United States of America</alt-title></titles><periodical><full-title>Proc Natl Acad Sci U S A</full-title></periodical><pages>4538-42</pages><volume>75</volume><number>9</number><edition>1978/09/01</edition><keywords><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Ascorbic Acid/ therapeutic use</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Methods</keyword><keyword>Middle Aged</keyword><keyword>Neoplasms/ drug therapy</keyword><keyword>Prognosis</keyword></keywords><dates><year>1978</year><pub-dates><date>Sep</date></pub-dates></dates><isbn>0027-8424 (Print)
0027-8424 (Linking)</isbn><accession-num>279931</accession-num><urls></urls><custom2>PMC336151</custom2><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>13, indications are that people with cancer receiving IVC often feel better and may possibly live longer.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DYW1lcm9uPC9BdXRob3I+PFllYXI+MTk3NjwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DYW1lcm9uPC9BdXRob3I+PFllYXI+MTk3NjwvWWVhcj48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ADDIN EN.CITE.DATA 14,15 Patients receiving IVC report less fatigue, nausea, vomiting, sleep problems and depression, as well as increased appetite and quality of life.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ecmlza288L0F1dGhvcj48WWVhcj4yMDAzPC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ecmlza288L0F1dGhvcj48WWVhcj4yMDAzPC9ZZWFyPjxS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ADDIN EN.CITE.DATA 4,6Other Conditions ADDIN EN.CITE <EndNote><Cite><Author>Kurbacher</Author><Year>1996</Year><RecNum>4260</RecNum><DisplayText><style face="superscript">16</style></DisplayText><record><rec-number>4260</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4260</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kurbacher, C. M.</author><author>Wagner, U.</author><author>Kolster, B.</author><author>Andreotti, P. E.</author><author>Krebs, D.</author><author>Bruckner, H. W.</author></authors></contributors><auth-address>Department of Gynecology and Obstetrics, University of Bonn Medical Center, Germany.</auth-address><titles><title>Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro</title><secondary-title>Cancer Lett</secondary-title><alt-title>Cancer letters</alt-title></titles><periodical><full-title>Cancer Lett</full-title></periodical><pages>183-9</pages><volume>103</volume><number>2</number><edition>1996/06/05</edition><keywords><keyword>Antineoplastic Agents/ administration & dosage</keyword><keyword>Ascorbic Acid/ administration & dosage</keyword><keyword>Breast Neoplasms/ drug therapy</keyword><keyword>Cell Survival/drug effects</keyword><keyword>Cisplatin/ administration & dosage</keyword><keyword>Doxorubicin/ administration & dosage</keyword><keyword>Drug Synergism</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Paclitaxel/ administration & dosage</keyword><keyword>Receptors, Estrogen/metabolism</keyword><keyword>Tumor Cells, Cultured</keyword></keywords><dates><year>1996</year><pub-dates><date>Jun 5</date></pub-dates></dates><isbn>0304-3835 (Print)
0304-3835 (Linking)</isbn><accession-num>8635156</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>16IVC is used to treat numerous other conditions, although these conditions have not been as extensively studied:infectionsrheumatoid arthritisfatigueIVC is considered to be part of complementary and alternative medicine and is not generally supported by mainstream medicine. ?Although there is some evidence for benefits from IVC, as referenced, we do not suggest it is scientifically validated.Side EffectsHigh dose IVC of up to 1.5g / kg (higher doses have also been used) given daily has been shown to be generally safe with few side-effects ADDIN EN.CITE <EndNote><Cite><Author>Riordan</Author><Year>2005</Year><RecNum>4239</RecNum><DisplayText><style face="superscript">17</style></DisplayText><record><rec-number>4239</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4239</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Riordan, H. D.</author><author>Casciari, J. J.</author><author>Gonzalez, M. J.</author><author>Riordan, N. H.</author><author>Miranda-Massari, J. R.</author><author>Taylor, P.</author><author>Jackson, J. A.</author></authors></contributors><auth-address>Biocommunication Research Institute, Center for the Improvement of Human Functioning, 3100 North Hillside Avenue, Wichita, KS 67219, USA.</auth-address><titles><title>A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients</title><secondary-title>P R Health Sci J</secondary-title><alt-title>Puerto Rico health sciences journal</alt-title></titles><periodical><full-title>P R Health Sci J</full-title><abbr-1>Puerto Rico health sciences journal</abbr-1></periodical><alt-periodical><full-title>P R Health Sci J</full-title><abbr-1>Puerto Rico health sciences journal</abbr-1></alt-periodical><pages>269-76</pages><volume>24</volume><number>4</number><edition>2006/03/31</edition><keywords><keyword>Ascorbic Acid/ administration & dosage</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Infusions, Intravenous</keyword><keyword>Male</keyword><keyword>Neoplasms/ drug therapy</keyword><keyword>Pilot Projects</keyword><keyword>Terminal Care</keyword><keyword>Vitamins/ administration & dosage</keyword></keywords><dates><year>2005</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>0738-0658 (Print)
0738-0658 (Linking)</isbn><accession-num>16570523</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>17 and can be used over a long period of time.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Hb256YWxlejwvQXV0aG9yPjxZZWFyPjIwMDU8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Hb256YWxlejwvQXV0aG9yPjxZZWFyPjIwMDU8L1llYXI+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ADDIN EN.CITE.DATA 5Other side-effects experienced by a small number of patients are related to the infusions of a concentrated fluid solution and include: abdominal cramps, diarrhea, nausea, vomiting, headache, dizziness, fatigue, facial flushing, perspiration and weakness. Irritation can occur at the site of the drip and recurrent infusions can cause thickening and collapse of the vein. These side-effects can usually be prevented by drinking fluids before and during the infusion and are also helped by the addition of calcium gluconate to the infusion (which we do routinely)PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib2ZmZXI8L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ib2ZmZXI8L0F1dGhvcj48WWVhcj4yMDA4PC9ZZWFyPjxS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ADDIN EN.CITE.DATA 2,9. If the needle becomes dislodged from the vein it can temporarily cause discomfort from the vitamin C escaping into the surrounding tissue.The development of kidney stones have been described in patients receiving IVC who had a past history of kidney stones. ADDIN EN.CITE <EndNote><Cite><Author>Mikirova</Author><Year>2013</Year><RecNum>4261</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>4261</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4261</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mikirova, N.A.; Casciari, J.J.; Hunninghake, R.E.; Riordan, N.H</author></authors></contributors><titles><title>Intravenous ascorbic acid protocol for cancer patients: scientifice rationale, pharmacology, and clinical experience</title><secondary-title>Functional Foods in Health and Disease</secondary-title></titles><periodical><full-title>Functional Foods in Health and Disease</full-title></periodical><pages>344-366</pages><volume>3</volume><number>8</number><dates><year>2013</year></dates><urls></urls></record></Cite></EndNote>2 However, whether the Vitamin C, the carrier fluid passing through the kidney or other factors cause the kidney stones is not known. IVC is not used in patients with severe kidney failure and a blood test for kidney function needs to be available prior to starting treatment and may be monitored at intervals during treatment. People with a rare genetic disorder called glucose-6-phosphate dehydrogenase deficiency are unable to tolerate high dose IVC. ADDIN EN.CITE <EndNote><Cite><Author>Levine</Author><Year>1999</Year><RecNum>4252</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>4252</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4252</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levine, M.</author><author>Rumsey, S. C.</author><author>Daruwala, R.</author><author>Park, J. B.</author><author>Wang, Y.</author></authors></contributors><auth-address>Molecular and Clinical Nutrition Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.</auth-address><titles><title>Criteria and recommendations for vitamin C intake</title><secondary-title>JAMA</secondary-title><alt-title>JAMA : the journal of the American Medical Association</alt-title></titles><periodical><full-title>Jama</full-title></periodical><pages>1415-23</pages><volume>281</volume><number>15</number><edition>1999/04/27</edition><keywords><keyword>Antioxidants</keyword><keyword>Ascorbic Acid/administration & dosage/adverse effects/chemistry/pharmacokinetics</keyword><keyword>Biological Availability</keyword><keyword>Free Radical Scavengers</keyword><keyword>Fruit</keyword><keyword>Humans</keyword><keyword>Nutrition Policy</keyword><keyword>Vegetables</keyword></keywords><dates><year>1999</year><pub-dates><date>Apr 21</date></pub-dates></dates><isbn>0098-7484 (Print)
0098-7484 (Linking)</isbn><accession-num>10217058</accession-num><urls></urls><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>18 You will need to have a blood test for this prior to receiving high dose IVC (there is now a charge for this test by Medlab and you will need to pay in cash when the blood is taken).IVC has occasionally caused severe bleeding from cancer tumours in a few patients with end-stage rapidly growing cancers.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DYW1lcm9uPC9BdXRob3I+PFllYXI+MTk3NDwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DYW1lcm9uPC9BdXRob3I+PFllYXI+MTk3NDwvWWVhcj48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ADDIN EN.CITE.DATA 19 Suddenly stopping high doses of vitamin c (whether taken by mouth or given intravenously) may cause a rebound effect resulting in suppressed immunity. In the early studies on IVC, patients were given up to 10g of Vitamin C by mouth when the IVC was stopped. ADDIN EN.CITE <EndNote><Cite><Author>Block</Author><Year>2003</Year><RecNum>4266</RecNum><DisplayText><style face="superscript">20</style></DisplayText><record><rec-number>4266</rec-number><foreign-keys><key app="EN" db-id="92ds25r2rtsetleeeesxzddjwxx5229220sx">4266</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Block, K. I.</author><author>Mead, M. N.</author></authors></contributors><auth-address>Block Center for Integrative Cancer Care, Evanston, Illinois 60201, USA.</auth-address><titles><title>Vitamin C in alternative cancer treatment: historical background</title><secondary-title>Integr Cancer Ther</secondary-title><alt-title>Integrative cancer therapies</alt-title></titles><periodical><full-title>Integr Cancer Ther</full-title><abbr-1>Integrative cancer therapies</abbr-1></periodical><alt-periodical><full-title>Integr Cancer Ther</full-title><abbr-1>Integrative cancer therapies</abbr-1></alt-periodical><pages>147-54</pages><volume>2</volume><number>2</number><edition>2004/03/24</edition><keywords><keyword>Antioxidants/therapeutic use</keyword><keyword>Ascorbic Acid/ therapeutic use</keyword><keyword>Complementary Therapies/methods</keyword><keyword>Controlled Clinical Trials as Topic</keyword><keyword>Dietary Supplements</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Neoplasms/ mortality/pathology/ therapy</keyword><keyword>Risk Assessment</keyword><keyword>Sensitivity and Specificity</keyword><keyword>Survival Analysis</keyword></keywords><dates><year>2003</year><pub-dates><date>Jun</date></pub-dates></dates><isbn>1534-7354 (Print)
1534-7354 (Linking)</isbn><accession-num>15035902</accession-num><urls></urls><electronic-resource-num>10.1177/1534735403002002007</electronic-resource-num><remote-database-provider>NLM</remote-database-provider><language>eng</language></record></Cite></EndNote>20Practical detailsAll patients need to sign a consent form. Scheduling of infusions is done either through the receptionists or by the doctor. It takes time to make up the IV fluids and they cannot be used after 24hrs once made up, so it is important to let us know if you are unable to attend an IV appointment, by 9am that day at the absolute latest (if an IV infusion has been prepared and a patient misses the appointment without letting us know, a fee for the infusion may be charged).References ADDIN EN.REFLIST 1.Cameron, E. & Pauling, L. Ascorbic acid and the glycosaminoglycans. An orthomolecular approach to cancer and other diseases. Oncology 27, 181-192 (1973).2.Mikirova, N.A.C., J.J.; Hunninghake, R.E.; Riordan, N.H. Intravenous ascorbic acid protocol for cancer patients: scientifice rationale, pharmacology, and clinical experience. Functional Foods in Health and Disease 3, 344-366 (2013).3.Abdel-Latif, M.M., Raouf, A.A., Sabra, K., Kelleher, D. & Reynolds, J.V. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. Journal of chemotherapy (Florence, Italy) 17, 539-549 (2005).4.Drisko, J.A., Chapman, J. & Hunter, V.J. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 22, 118-123 (2003).5.Gonzalez, M.J., et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integrative cancer therapies 4, 32-44 (2005).6.Yeom, C.H., Jung, G.C. & Song, K.J. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. Journal of Korean medical science 22, 7-11 (2007).7.Padayatty, S.J., et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140, 533-537 (2004).8.Levine, M.K., A.; Padayatty, S.J. Vitamin C. in Modern Nutrtion in Helath and Disease (ed. Shils, M.E.) (Lippincott Williams & Wilkins, Balitmore, 2005).9.Hoffer, L.J., et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19, 1969-1974 (2008).10.Sarna, S. & Bhola, R.K. Chemo-immunotherapeutical studies on Dalton's lymphoma in mice using cisplatin and ascorbic acid: synergistic antitumor effect in vivo and in vitro. Archivum immunologiae et therapiae experimentalis 41, 327-333 (1993).11.Nagy, B., Mucsi, I., Molnar, J., Varga, A. & Thurzo, L. Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro. In vivo (Athens, Greece) 17, 289-292 (2003).12.Lamson, D.W. & Brignall, M.S. Antioxidants and cancer therapy II: quick reference guide. Altern Med Rev 5, 152-163 (2000).13.Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75, 4538-4542 (1978).14.Cameron, E. & Pauling, L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73, 3685-3689 (1976).15.Murata, A., Morishige, F. & Yamaguchi, H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. International journal for vitamin and nutrition research. Supplement = Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Supplement 23, 103-113 (1982).16.Kurbacher, C.M., et al. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103, 183-189 (1996).17.Riordan, H.D., et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. Puerto Rico health sciences journal 24, 269-276 (2005).18.Levine, M., Rumsey, S.C., Daruwala, R., Park, J.B. & Wang, Y. Criteria and recommendations for vitamin C intake. JAMA 281, 1415-1423 (1999).19.Cameron, E. & Campbell, A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chemico-biological interactions 9, 285-315 (1974).20.Block, K.I. & Mead, M.N. Vitamin C in alternative cancer treatment: historical background. Integrative cancer therapies 2, 147-154 (2003). ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- rajiv gandhi university of health sciences bangalore
- the center for cancer and blood disorders
- intravenous fluid administration in the rau
- portsmouth hospitals procedural document template
- Фармацевтическая корпорация «Юрія Фарм»
- in
- intraoperative chemotherapy with a novel regimeregimen
- module 7 basics of cancer treatment
- mapua health
- cancer treatment chemotherapy alternatives
Related searches
- mental health awareness month mental health america
- mental health world health organization
- world health organization mental health definition
- dignity health behavioral health sacramento
- dignity health mental health sacramento
- advent health home health orlando
- world health organization health definition
- adventist health employee health plan
- advent health home health care
- advent health home health jobs
- advent health home health number
- adventist health employee health reedley